RT Journal Article
SR Electronic
T1 Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.07.20124636
DO 10.1101/2020.06.07.20124636
A1 Staines, Henry M
A1 Kirwan, Daniela E
A1 Clark, David J
A1 Adams, Emily R
A1 Augustin, Yolanda
A1 Byrne, Rachel L
A1 Cocozza, Michael
A1 Cubas-Atienzar, Ana I
A1 Cuevas, Luis E.
A1 Cusinato, Martina
A1 Davies, Benedict M O
A1 Davis, Mark
A1 Davis, Paul
A1 Duvoix, Annelyse
A1 Eckersley, Nicholas M
A1 Forton, Daniel
A1 Fraser, Alice J
A1 Garrod, Gala
A1 Hadcocks, Linda
A1 Hu, Qinxue
A1 Johnson, Michael
A1 Kay, Grant A
A1 Klekotko, Kesja
A1 Lewis, Zawditu
A1 Macallan, Derek C
A1 Mensah-Kane, Josephine
A1 Menzies, Stefanie
A1 Monahan, Irene
A1 Moore, Catherine M
A1 Nebe-von-Caron, Gerhard
A1 Owen, Sophie I
A1 Sainter, Chris
A1 Sall, Amadou A
A1 Schouten, James
A1 Williams, Chris
A1 Wilkins, John
A1 Woolston, Kevin
A1 Fitchett, Joseph R A
A1 Krishna, Sanjeev
A1 Planche, Tim
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.07.20124636.1.abstract
AB We report dynamics of seroconversion to SARS-CoV-2 infections detected by IgG ELISA in 177 individuals diagnosed by RT-PCR. Longitudinal analysis identifies 2-8.5% of individuals who do not seroconvert even weeks after infection. They are younger than seroconverters who have increased co-morbidity and higher inflammatory markers such as C-Reactive Protein. Higher antibody responses are associated with non-white ethnicity. Antibody responses do not decline during follow up almost to 2 months. Serological assays increase understanding of disease severity. Their application in regular surveillance will clarify the duration and protective nature of humoral responses to SARS-CoV-2.Competing Interest StatementSK is a member of the Scientific Advisory Committee for the Foundation for Innovative New Diagnostics (FIND) a not-for-profit organisation that produces global guidance on affordable diagnostics. The views expressed here are personal opinions and do not represent the recommendations of FIND. Clinical TrialCclinicaltrials.gov NCT04351646. Funding StatementThis study was supported by a DFID/Wellcome Trust Epidemic Preparedness coronavirus grant (220764/Z/20/Z) to JRAF, SK, HMS, ERA, LEC. HMS is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St Georges University of London. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board ethical approval (DARTS study - IRAS project ID: 282104; REC reference: 20/SC/0171).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary data for methods and results referred to in the manuscript is submitted together with the manuscript.